We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSchroder Asian Regulatory News (ATR)

Share Price Information for Schroder Asian (ATR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 432.00
Bid: 431.00
Ask: 433.00
Change: 2.00 (0.47%)
Spread: 2.00 (0.464%)
Open: 432.00
High: 434.00
Low: 425.00
Prev. Close: 430.00
ATR Live PriceLast checked at -
Schroder Asian Total Return is an Investment Trust

To provide a high rate of total return primarily through investment in equity and equity related securities in Asia Pacific Region (excluding Japan).

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results analysis from Kepler Trust Intelligence

19 Mar 2024 16:37

RNS Number : 4797H
Schroder Asian Total Retn InvCo PLC
19 March 2024
 

Schroder Asian Total Return (ATR)

19/03/2024

Results analysis from Kepler Trust Intelligence

Schroder Asian Total Return (ATR) has released its financial results for the year ending 31/12/2023. Over the year, the trust saw its NAV increase by 8.8% on a total return basis, compared to the benchmark return of 1.3%. The AIC sector average delivered a total return of -0.5%. 

Performance over the year has been primarily driven by stock selection, with the managers extracting positive attribution from 10 of the 12 countries in the index. Firstly, the managers' decision to avoid many Chinese companies delivered good relative returns. Secondly, the decision to allocate to a number of technology stocks also delivered strong performance.

Stock selection in India was a small relative detractor, but still contributed significant absolute returns. This was offset with performance elsewhere, and furthered long-term cumulative returns.

The trust announced a 4.5% increase in the dividend to 11.5p which indicates a prospective yield of c. 2.5% based on the current share price (as at 13/03/2024). The dividend was supported by revenue reserves which remain significant.

The discount narrowed slightly over the year to 4.6%. The board have been very active with share buy backs. In total, over 7.5% of the initial share capital was bought back over the course of 2023. 

Gearing has ranged between 4.6% and 10.3%, with an average level for the year of 7.9%.

Chair Sarah MacAulay commented on the trust's strong performance in a challenging period by saying "our unconstrained approach to investing in Asia has not only delivered good returns but also provided a degree of capital protection in difficult market conditions"

Kepler View

Schroder Asian Total Return (ATR) is a unique offering in the AIC Asia Pacific sector. Managers Robin Parbrook and King Fuei Lee take a benchmark agnostic approach that allows their stock selection capabilities to generate alpha, as well as using hedging strategies to help dampen volatility.

We believe the 2023 results represent a return to form and Robin and King Fuei. Their best returns came from stock selection in China, including the decision to avoid the big e-commerce names. Conversely, the names they did hold performed well and delivered significant alpha.

Stock selection alpha has been prevalent throughout the portfolio including in weak markets. Their tech holdings also rose significantly following increased demand which has been a positive tailwind.

Despite the excellent performance, the shares have traded at a persistent discount albeit the level is considerably narrower than the average of the peer group. The board has been active in trying to mitigate this and as such, we believe the current discount represents an attractive entry point for long-term investors.

The managers believe that many companies in the region are in good shape, which not only offers them a good foundation from which to deliver growth, but it also supports the dividend outlook for the region.

The portfolio continues to have an underweight allocation to China, and is overweight more developed Asia Pacific countries. The managers have considerable experience to support their top-down overlay, which we believe can help mitigate the worst of the region's risks. As such, we believe ATR may appeal to investors who maintain a cautious outlook on China, but still wish to capture many of Asia's exciting growth trends.

CLICK HERE TO READ THE FULL REPORT  Visit Kepler Trust Intelligence for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFZGMFVLDGDZM
Date   Source Headline
26th Apr 20244:27 pmRNSTransaction in Own Shares
26th Apr 202410:45 amRNSNet Asset Value(s)
25th Apr 202410:41 amRNSNet Asset Value(s)
24th Apr 20245:13 pmRNSResult of AGM
24th Apr 202410:26 amRNSNet Asset Value(s)
23rd Apr 202411:07 amRNSNet Asset Value(s)
22nd Apr 202410:33 amRNSNet Asset Value(s)
19th Apr 20242:03 pmRNSDirector/PDMR Shareholding
19th Apr 202410:14 amRNSNet Asset Value(s)
18th Apr 202410:17 amRNSNet Asset Value(s)
17th Apr 202410:35 amRNSNet Asset Value(s)
16th Apr 202410:34 amRNSNet Asset Value(s)
15th Apr 20245:46 pmRNSDirector/PDMR Shareholding
15th Apr 20244:46 pmRNSPortfolio Update
15th Apr 202411:36 amRNSNet Asset Value(s)
15th Apr 20247:00 amRNSAppointment of Non-Executive Director
12th Apr 202410:53 amRNSNet Asset Value(s)
11th Apr 202410:27 amRNSNet Asset Value(s)
10th Apr 202410:24 amRNSNet Asset Value(s)
9th Apr 202411:03 amRNSNet Asset Value(s)
8th Apr 202411:18 amRNSNet Asset Value(s)
5th Apr 202410:24 amRNSNet Asset Value(s)
4th Apr 202410:56 amRNSNet Asset Value(s)
3rd Apr 202410:34 amRNSNet Asset Value(s)
2nd Apr 202411:09 amRNSNet Asset Value(s)
28th Mar 20245:16 pmRNSTotal Voting Rights
28th Mar 20245:00 pmRNSTransaction in Own Shares
28th Mar 202411:12 amRNSNet Asset Value(s)
27th Mar 20245:33 pmRNSDirector Declaration
27th Mar 202410:56 amRNSNet Asset Value(s)
26th Mar 202411:25 amRNSNet Asset Value(s)
25th Mar 202411:17 amRNSNet Asset Value(s)
22nd Mar 20244:49 pmRNSTransaction in Own Shares
22nd Mar 202410:28 amRNSNet Asset Value(s)
21st Mar 202410:19 amRNSNet Asset Value(s)
20th Mar 202410:34 amRNSNet Asset Value(s)
19th Mar 20244:37 pmRNSResults analysis from Kepler Trust Intelligence
19th Mar 202410:40 amRNSNet Asset Value(s)
18th Mar 202410:41 amRNSNet Asset Value(s)
15th Mar 20245:00 pmRNSTransaction in Own Shares
15th Mar 20244:47 pmRNSSubmission of Documents
15th Mar 202410:32 amRNSNet Asset Value(s)
14th Mar 202410:35 amRNSNet Asset Value(s)
14th Mar 20247:01 amRNSDividend Declaration
14th Mar 20247:00 amRNSFinal Results
13th Mar 202410:25 amRNSNet Asset Value(s)
12th Mar 202410:51 amRNSNet Asset Value(s)
11th Mar 202410:50 amRNSNet Asset Value(s)
8th Mar 20244:32 pmRNSTransaction in Own Shares
8th Mar 202410:33 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.